Company Analysis

Alvotech Warrant ALVOW

A comprehensive view of key metrics, scores, and financial health for Alvotech Warrant

Overview of Alvotech

ALVOW NGM

Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech

Alvotech (ALVOW), in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.32, about 0.0% overvalued vs fair value, ranked 562/1122 in sector.

USD 0.32

31.25%

(Delayed)

• Vol 90d: 276.5%

52-Week Range

Low

0.18

73%

Now 0.32

High

0.37

Enterprise Value

Overall Score

View breakdown

Overall

Growth

Excellent

Profitability

Good

Health

Weak

Efficiency

Fair

Growth

Excellent

Profitability

Good

Health

Weak

Efficiency

Fair

Completeness: 62%

Confidence: 39%

Updated: Mar 8

Top Beats

Quick Facts

Website https://www.alvotech.com

HQ Luxembourg

Employees 1,012

Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data

Show more details

Shares outstanding missing or non-positive

Engine Room Money Flow™

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps

Total Revenue

$586.3M

19.7%%

Gross Profit

$350.8M

15.2%%

R&D Expense

$184.2M

7.5%%

Operating Income (EBIT)

$273.2M

529.8%%

Money Flow Bridge

You are currently seeing a limited view of the money flow waterfall.

See the full waterfall with all stages on Premium. Upgrade

Flow Direction: Money moves from left to right

Components: Breakdown shows composition of each stage

Industry-Specific: Pharmaceutical / Mature Biotech

Data Quality Notes

Negative operating cash flow is unusual for established pharma. This may indicate a transition period or should be investigated.
Negative free cash flow. Check if this is due to heavy CapEx, acquisitions, or operational challenges.
R&D intensity is 31.4% of revenue, indicating heavy investment in pipeline development.
Patent cliff risk: Monitor expiring exclusivity periods and pipeline readiness. Strong pharma companies have robust pipelines to replace expiring products.

Quality & Reliability Indicators

Cash Conversion

-18.4%

Poor

Weak cash conversion - investigate working capital

Locked Metric

Premium

Locked Metric

Premium

Locked Metric

Premium

Where It Leaks

Cash Flow Health critical

Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.

Active Leaks

1/4

Improving

High Impact

Critical

Medium

Stock-Based Compensation Leak

Current: 26.4%

Conversion Leak

Locked Leak

Upgrade to view details

Premium

Locked Leak

Upgrade to view details

Premium

Locked Leak

Upgrade to view details

Premium

Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing

Premium

Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.

For informational purposes only. Not investment advice.

Cost Advantage

Moderate

Customer Stickiness

Weak

Capital Efficiency

Moderate

Resilience

Developing

Scale & Market Position

Moderate

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 81% Coverage

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked

Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

95th percentile vs peers

Key Signals

Rev Growth YoY 4.36 96p Revenue CAGR 3Y 1.37 95p

Strengths

Growth performance in top 20% of peers (percentile: 95)
Rev Growth YoY in top 20% of peers (4.36, 96th percentile)
Revenue CAGR 3Y in top 20% of peers (1.37, 95th percentile)
Superior capital returns - 2 return metrics above peer median

Risks

No significant risks identified for this axis.

Profitability

46th percentile vs peers

Key Signals

Strengths

Risks

Premium

Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

32th percentile vs peers

Key Signals

Strengths

Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Alvotech Warrant.

WACC X.X%

X%XX%

Rev CAGR 5Y X.X%

-XX%XX%

Op Margin XX.X%

-XX%XX%

Adjust the sliders above to explore different valuation scenarios.

Unlock Premium

Reveal the full Scenario Theatre

See live sliders, narratives, and full Bear/Base/Bull outcomes.

Upgrade Now

Bear

- - -

- upside

Base

- - -

- upside

Bull

- - -

- upside

Fair Value Range Current: $-

$- $- $-

Alvotech Warrant ALVOW

Overview of Alvotech

Quick Facts

Next Events

Fair Value Snapshot

Flow Steps

Money Flow Bridge

Data Quality Notes

Quality & Reliability Indicators

Cash Conversion

Locked Metric

Locked Metric

Locked Metric

Stock-Based Compensation Leak

Locked Leak

Locked Leak

Locked Leak

Unlock full defense analysis

Pricing Power

Unlock full defense details

Cost Advantage

Unlock full defense details

Customer Stickiness

Unlock full defense details

Capital Efficiency

Unlock full defense details

Resilience

Unlock full defense details

Scale & Market Position

Unlock full defense details

Growth

Profitability

Safety

Actions & Info

Send Feedback